Pharmaceutical - UK, Pfizer

Filter

Current filters:

UKPfizer

Popular Filters

UK's NICE does not recommend Pfizer's Xiapex for Dupuytren's contracture

UK's NICE does not recommend Pfizer's Xiapex for Dupuytren's contracture

07-11-2014

The UK’s National Institute for Health and Care Excellence is consulting on provisional recommendations…

Anti-Arthritics/RheumaticsPfizerPharmaceuticalRegulationUKXiapex

MMIP formally established to boost medicines manufacturing in the UK

23-09-2014

A new Medicines Manufacturing Industry Partnership (MMIP) has been jointly established by the Association…

ActavisEisaiFujifilm Diosynth BiotechnologiesGlaxoSmithKlineOxford BioMedicaPfizerPharmaceuticalProductionUK

UK M&A regulator consults on more stringent regulations

UK M&A regulator consults on more stringent regulations

16-09-2014

Partly in response to the recent (failed, thus far) attempt by US pharma giant Pfizer to acquire Anglo-Swedish…

LegalMergers & AcquisitionsPfizerPharmaceuticalUK

Pfizer could try to acquire Actavis as back-up to a further bid for AstraZeneca

Pfizer could try to acquire Actavis as back-up to a further bid for AstraZeneca

22-08-2014

While speculation continues as to whether Pfizer will resume its attempts to buy AstraZeneca, Pfizer…

ActavisAstraZenecaBusiness FinanceIrelandMergers & AcquisitionsPfizerPharmaceuticalSwedenUKUnited StatesUSA

Seven pharma companies offer up compounds to UK researchers

Seven pharma companies offer up compounds to UK researchers

22-07-2014

UK researchers will be granted access to a ‘virtual library’ of deprioritized pharmaceutical compounds…

AstraZenecaEli LillyGlaxoSmithKlineJanssenMedical Research CouncilPfizerPharmaceuticalResearchTakeda PharmaceuticalUCBUK

UK Business Secretary to set out new takeover rules

UK Business Secretary to set out new takeover rules

13-07-2014

UK Business Secretary Vince Cable is shortly to announce new regulations to deal with foreign takeover…

LegalMergers & AcquisitionsPfizerPharmaceuticalUKVince Cable

England’s community prescribing rises almost 60% but costs increase only 15% in 10 years

England’s community prescribing rises almost 60% but costs increase only 15% in 10 years

09-07-2014

The number of prescription items dispensed in the community in England has increased by 58.5% over 10…

atorvastatinHealthcareLipitorPfizerPharmaceuticalUK

AstraZeneca accuses Pfizer of opportunism, as UK investigation kicks off

AstraZeneca accuses Pfizer of opportunism, as UK investigation kicks off

13-05-2014

As the arguments continue over the benefits or otherwise of US pharma giant Pfizer’s £63 billion ($106…

AstraZenecaMergers & AcquisitionsPfizerPharmaceuticalPoliticsUK

Potential to fast-track drugs in new Cancer Research UK partnership with AstraZeneca and Pfizer

Potential to fast-track drugs in new Cancer Research UK partnership with AstraZeneca and Pfizer

17-04-2014

British charity Cancer Research UK has joined forces with Anglo-Swedish drug major AstraZeneca and US…

AstraZenecaCancerHealthMajorMedicineOncologyPfizerPharmaceuticalPharmacologyResearchUK

Pharma Summit: Rethinking the future – new business models for pharma

Pharma Summit: Rethinking the future – new business models for pharma

14-03-2014

The way pharma works needs to change with an increasing focus on collaborations, sharing data and access…

HealthcareInterviewsLundbeckPfizerPharmaceuticalPricingUK

Back to top